

Listing of Claims

1-16 Canceled

17. (Original) A method of delivering an agent into the central nervous system of an animal comprising administering said animal said agent conjugated to a megalin binding moiety, wherein the transport of said agent conjugated to said megalin-binding moiety across the blood brain barrier of said animal is greater than the transport of said agent in the absence of conjugation to said megalin binding moiety.

18. (Currently amended) A method of increasing transcytosis of an agent across the blood-brain barrier of an animal, comprising conjugating said agent to a megalin-binding moiety, wherein transcytosis of said agent when conjugated to said megalin-binding moiety is greater than the transcytosis of said agent in the absence of said conjugation.

19. (Currently amended) A method of treating a disorder of the CNS in a mammal comprising administering to said animal a therapeutic agent conjugated to a megalin binding moiety.

20. Canceled

21. (Currently Amended) The method of claim 20, wherein said disorder is selected from the group consisting of Huntington's Disease, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, ischemia-related disease and stroke, spinal muscular atrophy, cerebellar degeneration, perivenous encephalitis, schizophrenia, epilepsy and a central nervous system cancer.

22. (Original) The method of claim 21, wherein said disorder is a central nervous system cancer and said agent is a cancer chemotherapeutic agent.

23-57. Canceled

58. (New) The method of claim 17 or 18 wherein the animal is a human.

59. (New) The method of claim 58 wherein the human is suffering from a disorder selected from the group consisting of Huntington's Disease, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, ischemia-

related disease and stroke, spinal muscular atrophy, cerebellar degeneration, perivenous encephalitis, schizophrenia, epilepsy and a central nervous system cancer.

60. (New) The method of claim 17 or 18 wherein the agent is a neurotrophic factor.

61. (New) The method of claim 17 or 18 wherein the therapeutic agent is a neurotrophic factor selected from the group consisting of Glial-Derived Neurotrophic Factor, Nerve Growth Factor, Brain-Derived Neurotrophic Factor, Neurotrophin-3, Neurotrophin-4/5, aFGF, bFGF, CNTF, Leukaemia Inhibitory Factor, Cardiotrophin-1, TGFb, BMPs, GDFs, Neurturin, Artemin, Persephin, EGF, TGFa, Neuregulins, IGF-1, IGF-2, ADNF and PDGF.

62. (New) The method of claim 17 or 18 wherein the therapeutic agent is brain-derived neurotrophic factor (BDNF).